These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 20610624

  • 1. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
    Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J, Chen J.
    Cancer Res; 2010 Jul 15; 70(14):6015-25. PubMed ID: 20610624
    [Abstract] [Full Text] [Related]

  • 2. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma.
    Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, Ye Q, Zeng X, Liao Q, Guo X, Li X, Ma J, Li G.
    J Cell Sci; 2011 Sep 01; 124(Pt 17):2997-3005. PubMed ID: 21878506
    [Abstract] [Full Text] [Related]

  • 3. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
    Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM, Chen J.
    Carcinogenesis; 2010 Oct 01; 31(10):1726-33. PubMed ID: 20675343
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
    Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY, Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, Zhang C, Wang JX, Ding YQ.
    J Pathol; 2014 Mar 01; 232(4):415-27. PubMed ID: 24293274
    [Abstract] [Full Text] [Related]

  • 6. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes.
    Keklikoglou I, Hosaka K, Bender C, Bott A, Koerner C, Mitra D, Will R, Woerner A, Muenstermann E, Wilhelm H, Cao Y, Wiemann S.
    Oncogene; 2015 Sep 10; 34(37):4867-78. PubMed ID: 25500542
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
    Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S, Fukayama M.
    Oncogene; 2014 May 08; 33(19):2454-63. PubMed ID: 23752186
    [Abstract] [Full Text] [Related]

  • 9. Identification of miR-143 as a tumour suppressor in nasopharyngeal carcinoma based on microRNA expression profiling.
    Xu YF, Li YQ, Guo R, He QM, Ren XY, Tang XR, Jia WH, Kang TB, Zeng MS, Sun Y, Ma J, Liu N.
    Int J Biochem Cell Biol; 2015 Apr 08; 61():120-8. PubMed ID: 25701793
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway.
    Li X, Deng SJ, Zhu S, Jin Y, Cui SP, Chen JY, Xiang C, Li QY, He C, Zhao SF, Chen HY, Niu Y, Liu Y, Deng SC, Wang CY, Zhao G.
    Oncotarget; 2016 Feb 02; 7(5):6000-14. PubMed ID: 26755660
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
    Crowley EH, Arena S, Lamba S, Di Nicolantonio F, Bardelli A.
    Hum Mutat; 2014 Feb 02; 35(2):208-14. PubMed ID: 24282149
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
    Rachagani S, Macha MA, Menning MS, Dey P, Pai P, Smith LM, Mo YY, Batra SK.
    Oncotarget; 2015 Nov 24; 6(37):40295-309. PubMed ID: 26516699
    [Abstract] [Full Text] [Related]

  • 19. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul 24; 3(7):OF20. PubMed ID: 23847364
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.